AVTE
Companies
NASDAQ
Aerovate Therapeutics Inc.
Health Care
$9.87
-$80.57 (-89.09%)
Price Chart
Overview
About AVTE
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Market Cap
$597.5M
Volume
811.6K
Avg. Volume
728.0K
P/E Ratio
-2.52
Dividend Yield
0.00%
Employees
28.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.78
Moderate Correlation
Volatility
High (0.77)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, AVTE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$597.5M
Volume811.6K
P/E Ratio-2.52
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 26, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025